logo
How China's Online Army Helped Beijing Fight US Tariff War

How China's Online Army Helped Beijing Fight US Tariff War

Newsweek21-05-2025
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A social network analysis firm says it has uncovered an operation involving over 1,000 fake accounts working to shape online discourse surrounding the United States-China trade war in Beijing's favor.
Newsweek reached out to the Chinese embassy in Washington, D.C., and the U.S. State Department via email for comment.
Why It Matters
The 90-day ceasefire reached in Geneva, Switzerland, by U.S. Treasury Secretary Scott Bessent and Chinese Vice Premier He Lifeng reduced duties on imported Chinese and U.S. goods by 145 and 125 percent, respectively. While the deal paused what had become a near-total embargo and bought negotiators time, tensions remain.
Trump has said the tariffs were necessary to end "unfair" treatment of U.S. exports, revive domestic manufacturing, and close the trade deficit with the U.S.'s third-largest trading partner. In its political messaging, Beijing has sought to rally other countries targeted by tariffs and cast itself as a defender of the global trade order, standing up to bullying.
What To Know
Graphika, a New York-based company that leverages AI to analyze online communities, says it has identified a network of more than 1,000 X (formerly Twitter) accounts seeking to influence perceptions of the trade war in the social media space.
"This included using fake personas purporting to be users in the U.S. and other countries, stealing content from authentic users, and the coordinated amplification of hashtags and media articles," the firm said in a report released Tuesday.
Social media accounts posing as real users posted and amplified content promoting the narrative that President Donald Trump's tariffs would harm American livelihoods and the global economy.
This file photo shows social media apps Bluesky, X, and Truth Social on a smartphone.
This file photo shows social media apps Bluesky, X, and Truth Social on a smartphone.
Getty Images
Other accounts advanced messages focused on international pushback to the U.S. from countries such as Japan, the United Kingdom, and Canada.
Suspected accounts in the network were reportedly easy to spot due to their "coordinated and inauthentic behaviors," Graphika said.
For instance, most featured combinations of Western first and last names, with both parts capitalized and joined, such as "BriannaShaw." The most commonly used default usernames are of a format assigned to new accounts, containing long sequences of random digits such as @GeorgeZip35528260.
Some accounts listed self-reported locations with glaring errors, such as repeating the same U.S. state three times.
Graphika said it was unable to definitively link the accounts to a specific actor or known influence operation.
"However, based on an analysis of content disseminated by the operation and similarities between the identified behaviors and past influence operations attributed to Chinese state actors, we assess that the network operator(s) were very likely aligned with the interests of China," the company said.
What People Are Saying
Chinese President Xi Jinping told representatives from the Community of Latin American and Caribbean States on May 13: "There are no winners in tariff wars or trade wars. Bullying or hegemonism only leads to self-isolation."
What Happens Next
Prices for some consumer goods are still expected to rise, though the three-month truce has averted the worst cost hikes.
Pending a deal, the U.S. retains a 30 percent tariff on Chinese goods—10 percent as a baseline, in line with most other countries, and an additional 20 percent tied to China's role as a major source of chemical precursors for fentanyl. China maintains a 10 percent baseline tariff on U.S. goods.
Graphika said it expects influence operations to continue seeking to shape online perceptions of U.S. trade policy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Telix Reports $204M Revenue, Up 63% YOY
Telix Reports $204M Revenue, Up 63% YOY

Yahoo

time21 minutes ago

  • Yahoo

Telix Reports $204M Revenue, Up 63% YOY

MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix') today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated otherwise. Q2 2025 Highlights Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® launched in the U.S. and commercial dose deliveries commenced. Gozellix has been assigned a Level II HCPCS code1 (effective 1 October 2025), a prerequisite for receiving Transitional Pass-Through payment status. ProstACT™ Global Phase 3 trial milestone – all 30 patients consented for Part 1. Global expansion with regulatory approvals to expand the trial into China, Japan and Canada. Q2 2025 Revenue (Unaudited) Revenue$M Q2 2025 Q2 2024 Variation Q1 2025 Variation Group revenue 204 125 63% 186 10% Global Illuccix® revenue 154 123 25% 151 2% RLS revenue1 46 - - 332 39% Commentary and business highlights Dr. Christian Behrenbruch, Managing Director and Group CEO, Telix, stated, 'Dose volumes for Illuccix rose 7% quarter-on-quarter in the U.S., reinforcing the strength of our market position and continued customer demand. Despite emerging competitive pricing pressure, we have effective strategies in place to manage impact to average selling price. This includes the recent launch of Gozellix which has been assigned a HCPCS code, a crucial reimbursement milestone towards pass-through status. We continue to show positive momentum across multiple assets in our therapeutic pipeline, including achievement of a key recruitment milestone in our ProstACT Global Phase 3 trial.' Therapeutics business TLX591 (177Lu-rosopatamab tetraxetan): Telix has consented all 30 patients required to complete Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate. Patients in two of the three arms (abiraterone and enzalutamide as standard of care) have completed dosing. An interim readout of safety and dosimetry will follow the completion of patient dosing, monitoring and data analysis. The trial is proceeding seamlessly into Part 2 at existing ex-U.S. sites and additional regulatory approvals have been obtained to commence the trial in China, Canada and Japan4. TLX592 (225Ac-PSMA-RADmAb): Telix has submitted a Human Research Ethics Committee (HREC) application in Australia for a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced metastatic castration resistant prostate cancer. TLX101 (131I-iodofalan, or 131I-IPA): Telix received HREC approval in Australia to commence IPAX BrIGHT, an international pivotal trial. An IPAX BrIGHT Clinical Trial Application (CTA) has also been submitted in Europe. TLX250 (¹⁷⁷Lu-DOTA-girentuximab): STARLITE-15 is enrolling patients. This Phase 1b/2 clinical trial is investigating the use of TLX250 in combination with cabozantinib and nivolumab, in clear cell renal cell carcinoma (ccRCC). Trial submission is in preparation for a pivotal trial of TLX250 as a monotherapy in advanced metastatic ccRCC, initially launching ex-U.S. TLX090 (¹⁵³Sm-DOTMP): In July, Telix submitted an Investigational New Drug (IND) application for a Phase 1 bridging study for Telix's therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone. Precision Medicine businessTelix received country-level approvals for Illuccix in France, Finland, Ireland, Sweden, Germany, Portugal, Greece, the Czech Republic, Belgium and Italy in Q2 and is launching on a market-by-market basis, as reimbursement is secured. Telix has completed enrolment of the Illuccix China Phase 3 study6, which will be used to file a marketing authorization in China in Q4 2025. Telix has received HREC approval in Australia and filed an IND with the FDA in the U.S. for a Phase 3 clinical trial aimed at expanding the label indication for Illuccix and Gozellix. The BiPASS study7 will evaluate the performance of MRI8 combined with PSMA PET9 imaging for detection and diagnosis of prostate cancer, which is designed to reduce the need for invasive biopsies. Telix has submitted a Prior Approval Supplement (PAS) to update the U.S. Prescribing Information for Illuccix. The proposed label expansion includes patient selection for radioligand therapy (RLT) in the pre-taxane setting. The prescribing information is expected to be updated, following FDA's review of the submission10. As part of product lifecycle management strategy, Telix announced a novel PET11 radiochemistry solution based on fluorine-18 (18F)-aluminium fluoride (AlF), branded AlFluor™12. The platform technology enables flexible radiolabeling of PSMA13 with either AlF or gallium-68 (68Ga). As part of the platform's development, Telix signed a strategic agreement with University Hospital Ghent and Ghent University for a novel [18F]AlF-PSMA-11 targeting agent, including extensive clinical data to enable a U.S. registration trial. Pixclara®14 (TLX101-CDx, 18F-floretyrosine or 18F-FET): A successful Type A meeting was held with the FDA on 24 June 2025, to agree on a path forward for resubmitting the New Drug Application (NDA) for Telix's brain cancer imaging candidate. Zircaix®15 (TLX250-CDx, 89Zr-DFO-girentuximab): The Company continues to progress a Biologics License Application (BLA) with the FDA for its kidney cancer PET imaging candidate. The PDUFA16 date remains 27 August 2025. Telix Manufacturing Solutions (TMS) Telix announced its Good Manufacturing Practice (GMP) manufacturing facility in Yokohama, Japan. Telix's first cyclotron facility in the Asia Pacific region represents a significant milestone in the Company's global manufacturing strategy. It will serve as a hub for commercial and clinical drug product supply, and future research and development in the region. The TMS facility in Brussels South (Seneffe), Belgium, produced its first GMP commercial radiopharmaceutical doses, marking the formal launch of Telix's radiopharmaceutical manufacturing capability in Europe. Corporate update Telix has received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates. The Company is fully cooperating with the SEC and is in the process of responding to the information request. At this stage, this matter is a fact-finding request. The Company has elected to notify the Australian Securities and Investments Commission of the SEC's information request. Telix's policy is not to discuss any details of an ongoing regulatory inquiry. The information request from the SEC does not mean that Telix or anyone else has violated United States federal securities laws or that the SEC has a negative opinion of any person, entity or security. We cannot predict when this matter will be resolved or what (if any) action the SEC may take following the conclusion of this investigation. While the matter is ongoing, Telix will continue with its clinical development programs relating to its prostate cancer therapy candidates, in the ordinary course of business. The information request does not extend to Telix's commercial and late-stage precision medicine products including Illuccix, Gozellix, Zircaix, Pixclara and Scintimun®. FY 2025 guidance Telix confirms FY 2025 revenue guidance of $770 million to $800 million17. Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS18. Telix confirms research and development (R&D) expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024. Guidance disclaimer The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below. Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix's ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, United Kingdom, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA19, and in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the FDA20. Telix's osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations (Global)Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Investor Relations (U.S.)Annie KasparianTelix Pharmaceuticals LimitedDirector Investor Relations and Corporate CommunicationsEmail: Media Contact Eliza Schleifstein Eliza@ This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors. Legal Notices Cautionary Statement Regarding Forward-Looking Statements. You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2025 Telix Pharmaceuticals Limited. All rights reserved. 1 Healthcare Common Procedure Coding System, refer to ASX disclosure 9 July 2025.2 Excludes revenue contribution from Illuccix sales.3 Revenue from date of RLS acquisition 27 January 2025.4 IND approved in China 22 July 2025; Clinical Trial Notification (CTN) approved in Japan 20 June 2025; Clinical Trial Application for Part 2 approved in Canada 22 May 2025.5 ID: NCT05663710.6 Refer to disclosure 13 May 2025.7 ID: NCT07052214.8 Magnetic resonance imaging.9 Imaging of prostate-specific membrane antigen with positron emission tomography.10 Subsequent to Telix disclosure on 23 June 2025, the FDA reclassified the submission to a PAS. The submission was made 5 June 2025.11 Positron Emission Tomography.12 Refer to ASX disclosure 20 June 2025.13 Prostate-specific membrane antigen.14 Brand name subject to final regulatory approval.15 Brand name subject to final regulatory approval.16 Prescription Drug User Fee Act. 17 Refer to ASX disclosures 20 February 2025. 18 See Guidance Disclaimer for further information.19 Telix ASX disclosure 20 December 2021.20 Telix ASX disclosure 21 March 2025.

Gabbard yells 'Russia hoax' to distract MAGA from Epstein for Trump. It won't last.
Gabbard yells 'Russia hoax' to distract MAGA from Epstein for Trump. It won't last.

USA Today

time22 minutes ago

  • USA Today

Gabbard yells 'Russia hoax' to distract MAGA from Epstein for Trump. It won't last.

Say what you want about AI, but powerful artificial intelligence in the hands of a 79-year-old man with zero emotional intelligence makes for ugly outcomes. Tulsi Gabbard was on the outs – literally and figuratively – with President Donald Trump last month after contradicting him about Iran's nuclear program, which he was about to bomb. Gabbard, Trump's Director of National Intelligence, was shut out of planning meetings about Iran and pushed to the intelligence sidelines for asserting that Iran had not been trying to build a nuclear weapon. "I don't care what she said," Trump replied when asked about Gabbard back then. She needed a way back inside Trump's bubble. The president's new "Epstein files" scandal offered an opportunity. Trump has stumbled badly with his loyal base and MAGA influencers by demanding that they just move on from a favorite conspiracy theory: that Jeffrey Epstein was murdered in 2019 to prevent disclosure of his "client list" of famous, powerful, wealthy people he had blackmailed. Epstein, you must know by now, was a former Trump cruising buddy and convicted pedophile who died by suicide in federal prison in 2019 while awaiting trial on sex trafficking charges filed during Trump's first term. Trump has long relied on distraction tactics when his supporters get antsy, like a weary parent shaking car keys in a baby's face to stop the crying. But that wasn't working this time. MAGA was in a meltdown. The base was not buying Trump's new pitch: that the Epstein files they so desperately want to see were a Democratic "hoax." So Gabbard dug deep into the classics of Trump's "hoax" claims, declaring on July 18 that President Barack Obama's top advisors had somehow concocted the notion that Russia had attempted to interfere in the 2016 presidential election, which Trump won while defeating Hillary Clinton. Tulsi Gabbard caters to Trump by suggesting Obama is a criminal Gabbard issued a July 18 memo claiming to have new evidence of an "Obama Administration conspiracy to subvert" Trump's 2016 win. She pushed it in a post on X, announcing that she was sending information to the Department of Justice for "criminal referral." And she played it up for the weekend morning anchors at Fox News, because, of course. Trump grabbed all that like a drowning man grabs a life preserver. He spent the weekend frenzy-posting on his website, Truth Social, promoting Gabbard's Fox News hit, posting memes of Obama and other prominent Democrats in a jail cell and in prison uniforms. The president of the United States of America even shared a video made with artificial intelligence of Obama being handcuffed in the Oval Office. Say what you want about AI, but powerful artificial intelligence in the hands of a 79-year-old man with zero emotional intelligence makes for ugly outcomes. 'Stupid Republicans': Trump mocks GOP allies for seeking Epstein files release | Opinion Trump and Gabbard won't let facts get in the way of their fresh lies The lit sparkler Gabbard passed off as a bombshell focuses on the discussion within the intelligence community at the end of Obama's second term about whether Russia had used cyberattacks on election infrastructure. She's claiming Obama's team "manufactured" intelligence to hobble Trump's impending presidency after he won. There's a hole in that theory. First, the Obama administration said shortly after the 2016 presidential election that hackers had not tampered with the election results. Marc Elias, who then was general counsel for the Clinton campaign, wrote at the time that they had "not uncovered any actionable evidence of hacking" in the election. Opinion: Trump is unpopular, polls show, and he's building an America most Americans hate Trump's tantrums about this have never been focused just on cyberattacks or hacking. He has long insisted that any claim that "Russia, Russia, Russia" wanted him to win in 2016 was a "hoax." Here's another problem with that. The U.S. Senate Select Committee on Intelligence, in an August 2020 report issued as Trump was running for re-election, said it "found irrefutable evidence of Russian meddling" in the election, including "an aggressive, multi-faceted effort to influence, or attempt to influence, the outcome." Those words came from the archived statement by Marco Rubio, who at the time was a Republican senator from Florida and acting chairman of the Intelligence Committee, and now serves as Trump's secretary of State. He and Gabbard are, in theory, on the same team. You know who else is on that team? CIA Director John Ratcliffe, who earlier this month released a review of his agency's 2016 assessment that Russia tried to interfere with the 2016 election. That review offered some criticism for how the assessment was reached, but didn't challenge its veracity. Gabbard is hoping that Americans will be distracted U.S. Sen. Mark Warner of Virginia, the ranking Democrat on the Intelligence Committee, put out that 966-page 2020 report about Russia with Rubio and still holds that post today. The report's title: "Russian Active Measures Campaigns and Interference in the 2016 Election." Warner, in a July 18 statement, said, "It seems DNI Gabbard is unaware" that the committee found that Russia "used social media to conduct an information warfare campaign in order to benefit Donald Trump." He also noted, "This conclusion was supported on a unanimous basis by every single Democrat and Republican on the committee." Gabbard is dredging back up Russian interference because American voters just don't buy what Trump has tried to sell them about the Epstein files that his administration is still keeping secret, after he promised during last year's campaign to make them public. She appears to have won back his favor, for now. But this distraction is just so shaky, like those keys dangled in a baby's face, that it won't hold America's gaze for long. Follow USA TODAY columnist Chris Brennan on X, formerly known as Twitter: @ByChrisBrennan. Sign up for his weekly newsletter, Translating Politics, here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store